Theralase Technologies Inc. V.TLT

Comparisons of single agents

[enriquesuave]

90 days         12 months               # of treatments in 12 months period 

Keytruda.    41%.                   19%.                    18. IV

Vicinium.     42%.                    17%.                    36

Adstiladrin.  50%.                    24%.                     4

TLD-1433.   50%.                    25%.                     2.         Non optimized evaluable patients 

TLD-1433.   60%.                    11.1%.                  2.          Too early to assess not enough data


Data is beating all single agents and potential for PR patients to convert to CR status increases the potential to beat present data.

[ScienceFirst]

Enriquesuave ... Great post.  Comparison table like you just showed is the proper thing that all investors should focus on. You list Vicinium in your table.  The FDA didn't approve it in 2021 because of clinical data and manufacturing issues. Additional clinical and statistical data and analyses are being requested by the FDA to potentially approve the agent for this 

[enriquesuave]

From the percentages used, we can see that they are counting the 4 patients from the 1st set of 12 who got a second optimized treatment but not a first. 27 patients total.  Affects the long term results as they will not have received 2 optimized treatments, but only 1. IMO. Plus we have one patient who sadly passed away and is included.  So at 450 days in Optimized group, we have 1

[Legit62]

Any idea when those reports will come based on this data? Blood bath today on news that looked promising when all said and done